Cargando…

Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis

The Chinese government has launched six rounds of national drug price negotiation since 2016 to lower the price and expand access to innovative drugs, many of which are anticancer drugs. This study aims to examine the effect of the second round of negotiation at the provincial level on the expenditu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yan, Zhu, Zheng, Zhang, Jiawei, Han, Peien, Qi, Yu, Wang, Xiaoyang, Yang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025142/ https://www.ncbi.nlm.nih.gov/pubmed/35457445 http://dx.doi.org/10.3390/ijerph19084578

Ejemplares similares

Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study
por: Cai, Lele, et al.
Publicado: (2022)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
por: Zhu, Hong, et al.
Publicado: (2022)

The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis
por: Ding, Yi, et al.
Publicado: (2022)

Negotiating prices of drugs for rare diseases
por: Henrard, Séverine, et al.
Publicado: (2016)

The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis
por: Yang, Ying, et al.
Publicado: (2021)

The impact of zero markup drug policy on patients' healthcare utilization and expense: An interrupted time series study
por: Zhu, Zheng, et al.
Publicado: (2022)

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022)

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
por: Wang, Ni, et al.
Publicado: (2021)

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
por: Mingge, Xia, et al.
Publicado: (2023)

The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China
por: Bao, Yuwen, et al.
Publicado: (2023)

Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
por: Yi, Hongbin, et al.
Publicado: (2023)

Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study
por: Wang, Xiaoyang, et al.
Publicado: (2023)

Effects of Chinese medical pricing reform on the structure of hospital revenue and healthcare expenditure in county hospital: an interrupted time series analysis
por: Liu, Mengling, et al.
Publicado: (2021)

Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis
por: Liu, Yanyan, et al.
Publicado: (2022)

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis
por: Huang, Cong, et al.
Publicado: (2021)

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
por: Zhang, Yichen, et al.
Publicado: (2021)

The Impact of Prescribing Monitoring Policy on Drug Use and Expenditures in China: A Multi-center Interrupted Time Series Study
por: Nie, Xiaoyan, et al.
Publicado: (2023)

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
por: Huang, Cong, et al.
Publicado: (2022)

Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
por: Jaksa, Ashley, et al.
Publicado: (2023)

Does drug price-regulation affect healthcare expenditures?
por: Ben-Aharon, Omer, et al.
Publicado: (2016)

Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia
por: Babar, Zaheer Ud Din, et al.
Publicado: (2007)

Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls
por: Chen, Yilin, et al.
Publicado: (2021)

Impact of the Drug Prices Control Order (2013) on the Utilization of Anticancer Medicines in India: An Interrupted Time-Series Analysis
por: Sharma, Bhavna, et al.
Publicado: (2022)

Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study
por: Guan, Xiaodong, et al.
Publicado: (2019)

The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis
por: Wang, Xiao, et al.
Publicado: (2023)

Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea
por: Yoo, Ki-Bong, et al.
Publicado: (2015)

Payer-Negotiated Prices for Telemedicine Services
por: Wu, Shannon S., et al.
Publicado: (2022)

The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis
por: Rong, Xuejing, et al.
Publicado: (2020)

Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
por: Rawson, Nigel S. B.
Publicado: (2022)

Impact of the Low-Price Medicine Policy on Medicine Supply in China: An Interrupted Time-Series Analysis
por: Zhao, Mingyue, et al.
Publicado: (2021)

Price Increases and New Drugs Drive Increased Expenditures for Multiple Sclerosis
por: Schafer, Jeremy A., et al.
Publicado: (2010)

Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China
por: Yuan, Jing, et al.
Publicado: (2021)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
por: Wu, Di, et al.
Publicado: (2022)

Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship
por: Messori, Andrea
Publicado: (2016)

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
por: Chen, Lei, et al.
Publicado: (2020)

Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016–2018: an interrupted time series study in Shaanxi
por: Yan, Kangkang, et al.
Publicado: (2020)

Fee-for-value in the pharmaceutical industry: a policy framework applying data science to negotiate drug prices
por: Patel, Nisarg A.
Publicado: (2017)

Using strategic price negotiations to contain costs and expand access to medicines in China
por: Si, Lei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_77ee0ojkghp3pmdnjadgvnh9s6